Can Multigene Tests Guide Adjuvant Treatment in Early Breast Cancer?
Breast cancer is heterogeneous, and predicting outcomes using clinical and pathologic features can be challenging. Genomic tests such as Oncotype DX, PAM50, and MammaPrint have been developed to aid in treatment decisions since 2002. Studies like the NSABP B-14 and B-20 trials have shown the benefit
0 views • 45 slides
Summary of NSABP Protocols in Breast Cancer Studies
NSABP conducted various adjuvant and neoadjuvant trials (B-15, B-18, B-22, B-23, B-28, B-30, B-27, B-40) involving different treatment arms and patient populations with operable breast cancer. Trials included chemotherapy regimens with Adriamycin, cyclophosphamide, tamoxifen, and radiation therapy,
0 views • 11 slides